전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-4 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,016 programs
CGTLimited DatastaleChinese PLA General HospitalPhase 2

CART-EGFR (CART-EGFR)

Advanced EGFR-positive Solid Tumors · EGFR

#EGFR#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 9Status Active
AntibodyLimited DatastaleGlaxoSmithKlinePhase 2

Feladilimab (Feladilimab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#monoclonal-antibody#GlaxoSmithKline
Trials 9Status Recruiting
CGTLimited DatastaleNanjing IASO Biotechnology Co.,…Phase 2

Eque-cel (Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection, Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (Eque-cel))

Relapsed/Refractory Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 9Status Recruiting
CGTAAVLimited DatastaleNovartis PharmaceuticalsPhase 2

Rapcabtagene autoleucel (Rapcabtagene autoleucel)

Idiopathic Inflammatory Myopathies · ANCA Associated Vasculitis (AAV)

#ANCAAssociatedVasculitisAAV#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 9Status Recruiting
CGTCurated CorestaleKitePhase 2

Tecartus (Tecartus)

Acute Lymphoblastic Leukemia; Large B-cell Lymphoma · Acute Lymphoblastic Leukemia

#AcuteLymphoblasticLeukemia#CGT#Phase2#BioJungboMoa-pick#cell-gene-therapy+4
Trials 9Status Recruiting
AntibodyLimited DatastaleXencor, Inc.Phase 2

XmAb20717 (XmAb20717)

Biliary Tract Cancer · Melanoma

#Melanoma#Antibody#Phase2#monoclonal-antibody#BiliaryTractCancer+1
Trials 9Status Recruiting
ADCStandard DatabasestaleCelldex TherapeuticsPhase 2

glembatumumab vedotin (glembatumumab vedotin)

Advanced Malignant Solid Neoplasm; Estrogen Receptor Negative · Melanoma

#Melanoma#ADC#Phase2#antibody-drug-conjugate#AdvancedMalignantSolidNeoplasm+2
Trials 9Status Active
CGTLimited DatastaleHebei Senlang Biotechnology Inc…Phase 1

Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells (Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells)

19 and 22+ B Cell Hematologic Tumors; 19 and 20+ B Cell Hematologic Tumors · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 8Status Recruiting
AntibodyLimited DatastaleJin-hong ChenPhase 2

Cadonilimab+regorafenib (Cadonilimab+regorafenib)

Advanced Hepatocellular Carcinoma · Advanced Hepatocellular Carcinoma

#AdvancedHepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Jin-hong
Trials 8Status Active
ADCLimited DatastaleAbbViePhase 3

Depatuxizumab mafodotin (Depatuxizumab mafodotin)

Glioblastoma · Glioblastoma

#Glioblastoma#ADC#Phase3#antibody-drug-conjugate#AbbVie
Trials 8Status Active
AntibodyLimited DatastaleMacroGenicsPhase 2

Flotetuzumab (Flotetuzumab)

Relapsed Acute Myeloid Leukemia · Relapsed Acute Myeloid Leukemia

#RelapsedAcuteMyeloidLeukemia#Antibody#Phase2#monoclonal-antibody#MacroGenics
Trials 8Status Discontinued
CGTStandard DatabasestaleThe First Hospital of Jilin Uni…Phase 2

IL-15-armored CAR-T cells (IL-15-armored CAR-T cells)

Relapsed/Refractory Multiple Myeloma; Plasma Cell Leukemia (PCL) · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 8Status Recruiting
CGTLimited DatastaleMiltenyi Biotec, Inc.Phase 1

Autologous CAR19 T lymphocytes (Autologous CAR19 T lymphocytes)

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia; Non-Hodgkin's Lymphoma Refractory · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 7Status Recruiting
AntibodyLimited DatastaleHoffmann-La RochePhase 3

Emactuzumab (Emactuzumab)

Cancer · Cancer

#Cancer#Antibody#Phase3#monoclonal-antibody#Hoffmann-La
Trials 7Status Recruiting
CGTLimited DatastaleSichuan UniversityPhase 1

EpCAM CAR-T cells (EpCAM CAR-T cells)

Malignant Neoplasm of Nasopharynx TNM Staging Distant Metastasis (M); Breast Cancer Recurrent · Malignant Neoplasm of Nasopharynx TNM St

#MalignantNeoplasmofNasopharynxTN#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 7Status Active
AntibodyLimited DatastaleImmunoGen, Inc.Phase 2

Lorvotuzumab Mertansine (Lorvotuzumab Mertansine)

Pleuropulmonary Blastoma; Recurrent Malignant Peripheral Nerve Sheath Tumor · Pleuropulmonary Blastoma

#PleuropulmonaryBlastoma#Antibody#Phase2#monoclonal-antibody#RecurrentMalignantPeripheralNerv+1
Trials 7Status Active
CGTLimited DatastaleMiltenyi Biomedicine GmbHPhase 2

MB-CART19.1 (MB-CART19.1)

Precursor B-Lymphoblastic Lymphoma/Leukaemia Refractory · Melanoma Stage III

#MelanomaStageIII#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 7Status Active
ADCStandard DatabasestaleQuantumLeap Healthcare Collabor…Phase 2

[vic-]trastuzumab duocarmazine (SYD985, SYD985 ([vic-]trastuzumab duocarmazine))

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastNeoplasms+2
Trials 7Status Recruiting
CGTLimited DatastaleStephan Grupp MD PhDPhase 2

CART22-65s (Autologous, humanized anti-CD22 CAR T cell therapy, Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s))

B-cell Acute Lymphoblastic Leukemia; B Lineage Lymphoblastic Lymphoma · CD22

#CD22#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 6Status Recruiting
ADCLimited DatastaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab mafodotin lyophilized powder)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#antibody-drug-conjugate#GSK
Trials 6Status Active

12 / 51 pages

← PreviousNext →